Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737706 · ClinicalTrials.gov registry record · Phase 1
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT05737706: Clinical Trial Phase 1 study, sponsored by Mirati Therapeutics.
NCT05737706 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05737706, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Interventions
- DRUG MRTX1133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2025-03-10 |
| Phase | Phase 1 |
Why NCT05737706 stopped before completion
NCT05737706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which MRTX1133 is the first listed.
NCT05737706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05737706 about?
NCT05737706 is a clinical study titled "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation". A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
What is the current status of trial NCT05737706?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-03-06. Estimated completion is 2025-03-10.
What interventions are being tested in trial NCT05737706?
The interventions under investigation include: MRTX1133 (DRUG).
Who is sponsoring clinical trial NCT05737706?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05737706's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI